Zimbabwe has officially withdrawn from negotiations for a $367 million health funding agreement with the United States. This decision follows a leaked government memo from December 2025, which revealed that President Emmerson Mnangagwa considered the deal “lopsided.” The five-year pact, proposed under Washington’s new “America First Global Health Strategy,” sought to address HIV/AIDS, malaria, and tuberculosis. However, the Zimbabwean government argued that the conditions attached to the aid posed an unacceptable threat to national sovereignty.
At the heart of the dispute is a demand for sensitive biological resources. Government spokesperson Nick Mangwana explained that the U.S. required long-term access to Zimbabwe’s health data and physical pathogen specimens. Furthermore, he noted that the deal offered no guarantee that Zimbabwe would share in the benefits of future vaccines or treatments. Consequently, Harare viewed the arrangement as an “unequal exchange” where the nation provided raw scientific materials without securing the final medical products for its own people.
The collapse of the Zimbabwe US Health Deal coincides with a broader shift in U.S. foreign policy. Since returning to office in January 2025, President Donald Trump has systematically dismantled the U.S. Agency for International Development (USAID). This agency formerly managed billions in global aid, but its functions have now been absorbed into the State Department. Meanwhile, the U.S. officially completed its withdrawal from the World Health Organization (WHO) in January 2026. This move has pushed Washington to pursue bilateral deals that critics describe as “resource-for-aid” traps.
Zimbabwe is not the only African nation to express such reservations. In late 2025, Kenya’s High Court suspended a similar $1.6 billion health agreement following a petition by consumer rights groups. Those groups argued that the deal violated national data protection laws. Moreover, reports suggest that U.S. negotiators attempted to link health funding to access to Zimbabwe’s critical minerals, such as lithium. This perceived “modern-day resource colonialism” has triggered a wave of resistance across the continent.
In response to the rejection, U.S. Ambassador Pamela Tremont announced that Washington will now begin the “difficult and regrettable task” of winding down its health assistance. This withdrawal places roughly 1.2 million Zimbabweans currently receiving U.S.-supported HIV treatment in a vulnerable position. Nevertheless, Harare remains firm. Officials insist that any future cooperation must respect the dignity of the nation and adhere to multilateral standards, such as those set by the WHO’s pathogen-sharing schemes.
Ultimately, the failure of the Zimbabwe US Health Deal highlights a growing geopolitical divide. While 14 other African countries have signed similar bilateral pacts, Zimbabwe’s rejection signals a desire for “African solutions” to health crises. As the country halts raw mineral exports to bolster its own economy, it is also drawing a “red line” on its biological data. The outcome of this standoff will likely define the future of health diplomacy between Washington and the Global South for years to come.
READ: Africa CDC FHI 360 Partnership Strengthens Health Security
